Month: February 2024

MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference. TD Cowen | Boston, MA | March 4-6, 2024Presentation: Monday, March 4, 2024 at 2:10 PM ETWebcast: Click here to access Institutional investors interested in meeting with senior management may contact their TD Cowen representative. A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the link above. A replay will be available on the Company’s website following the event. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage...

CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 2024 BIO CEO & Investor Conference, taking place February 26-27, 2024, in New York, NY.2024 BIO CEO & Investor Conference  Format: Presentation and one-on-one investor meetingsDate: Monday, February 26, 2023 Time: 2:45 p.m. ETLocation: New York, NYTo register for the conference and schedule a one-on-one meeting with Reviva management, please use the link HERE. About Reviva Reviva is a late-stage...

The highly integrated 3.3 kV XIFM plug-and-play digital gate driver is designed to work out-of-the-box with high-voltage SiC-based power modules to simplify and speed system integration CHANDLER, Ariz., Feb. 20, 2024 (GLOBE NEWSWIRE) — The electrification of everything is driving the widespread adoption of Silicon Carbide (SiC) technology in medium-to-high-voltage applications like transportation, electric grids and heavy-duty vehicles. To help developers implement SiC solutions and fast-track the development process, Microchip Technology (Nasdaq: MCHP) today introduces the 3.3 kV XIFM plug-and-play mSiC™ gate driver with patented Augmented Switching™ technology, which is designed to work out-of-the-box with preconfigured module settings to significantly reduce design and evaluation time. To speed time to market,...

– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase 1/2a clinical trial in 2024 – CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) who have failed one line of treatment. IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily...

EL SEGUNDO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) — Big 5 Sporting Goods Corporation (Nasdaq: BGFV) (the “Company”), a leading sporting goods retailer, will announce fourth quarter and full year fiscal 2023 financial results on Tuesday, February 27, 2024, after the market close. The Company will host a conference call to discuss these results and provide additional comments and details. The conference call is scheduled to begin at 2:00 p.m. Pacific Time on Tuesday, February 27, 2024. To access the conference call, participants in North America may dial (877) 407-9039 and international participants may dial (201) 689-8470. Participants are encouraged to dial in to the conference call ten minutes prior to the scheduled start time. In addition, the call will be broadcast live over the Internet and accessible through the Company’s...

DALLAS, Feb. 20, 2024 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader of access, optical and AI-driven cloud software solutions, today announced that Todd Jackson and Paul Choi have been appointed to the company’s Board of Directors. Jackson and Choi join the DZS Board following three strategic transactions: securing $25 million of working capital through two transactions, a private placement of DZS common stock and a term loan; the planned divestiture of the company’s lower margin Asia business, which, upon closing, will eliminate $43 million of debt; and an additional $5 million of working capital. The sale of the Asia business is expected to close in the first quarter of 2024. Jackson is an accomplished attorney who brings to the DZS Board 30 years of M&A advisory and transaction experience with over $30 billion...

BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City. Dr. Mazzo’s presentation is on Monday, February 26, 2024 at 11:15 a.m. Eastern time. Management will also be available for in-person one-on-one meetings with investors. For those interested in meeting with management during the conference, please request a meeting through the online conference platform or reach out to John Menditto, VP...

Event to feature KOL perspective on emerging MASH therapies SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET. To register, click here. During...

CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m. ET in New York City. Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.   Tonix Pharmaceuticals Holding Corp.* Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio...

VANCOUVER, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced C$1,000,000 non-brokered private placement (the “Offering”) by issuing 11,028,429 units (the “Units”) at a price of C$0.05 per Unit, for gross proceeds of C$551,421. Each Unit consists of one Sonoro common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of three years from the closing of the private placement at an exercise price of C$0.07 per share. The net proceeds from the Offering will be used to fund the ongoing development of the Company’s Cerro Caliche gold project in Sonora, Mexico. All...